SYRE
Price
$33.07
Change
-$0.09 (-0.27%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
2.57B
42 days until earnings call
Intraday BUY SELL Signals
VSTM
Price
$6.59
Change
-$0.20 (-2.95%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
510.67M
Intraday BUY SELL Signals
Interact to see
Advertisement

SYRE vs VSTM

Header iconSYRE vs VSTM Comparison
Open Charts SYRE vs VSTMBanner chart's image
Spyre Therapeutics
Price$33.07
Change-$0.09 (-0.27%)
Volume$5.45K
Capitalization2.57B
Verastem
Price$6.59
Change-$0.20 (-2.95%)
Volume$47.59K
Capitalization510.67M
SYRE vs VSTM Comparison Chart in %
SYRE
Daily Signal:
Gain/Loss:
VSTM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SYRE vs. VSTM commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Hold and VSTM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (SYRE: $33.16 vs. VSTM: $6.79)
Brand notoriety: SYRE and VSTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 139% vs. VSTM: 95%
Market capitalization -- SYRE: $2.57B vs. VSTM: $510.67M
SYRE [@Biotechnology] is valued at $2.57B. VSTM’s [@Biotechnology] market capitalization is $510.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileVSTM’s FA Score has 0 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • VSTM’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than VSTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 3 TA indicator(s) are bullish while VSTM’s TA Score has 4 bullish TA indicator(s).

  • SYRE’s TA Score: 3 bullish, 5 bearish.
  • VSTM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both SYRE and VSTM are a bad buy in the short-term.

Price Growth

SYRE (@Biotechnology) experienced а +6.80% price change this week, while VSTM (@Biotechnology) price change was -11.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($2.57B) has a higher market cap than VSTM($511M). SYRE YTD gains are higher at: 1.221 vs. VSTM (-12.047). SYRE has higher annual earnings (EBITDA): -223.64M vs. VSTM (-238.62M). SYRE has more cash in the bank: 486M vs. VSTM (138M). SYRE has less debt than VSTM: SYRE (0) vs VSTM (89.5M). VSTM has higher revenues than SYRE: VSTM (13.4M) vs SYRE (0).
SYREVSTMSYRE / VSTM
Capitalization2.57B511M504%
EBITDA-223.64M-238.62M94%
Gain YTD1.221-12.047-10%
P/E Ratio1.72N/A-
Revenue013.4M-
Total Cash486M138M352%
Total Debt089.5M-
FUNDAMENTALS RATINGS
SYRE vs VSTM: Fundamental Ratings
SYRE
VSTM
OUTLOOK RATING
1..100
5876
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3962
P/E GROWTH RATING
1..100
82100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VSTM's Valuation (61) in the Biotechnology industry is in the same range as SYRE (71) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to SYRE’s over the last 12 months.

VSTM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VSTM’s over the last 12 months.

SYRE's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as VSTM (62) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VSTM’s over the last 12 months.

SYRE's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VSTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREVSTM
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
SYRE
Daily Signal:
Gain/Loss:
VSTM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MUBFX34.960.24
+0.69%
NYLI WMC Value Class I
CGIFX46.440.17
+0.37%
American Funds Intl Gr and Inc 529F1
GERCX11.850.01
+0.08%
Goldman Sachs Em Mkts Eq Insghts C
SPXKX84.40-0.45
-0.53%
Shelton S&P 500 Index K
SGFCX47.19-0.54
-1.13%
Sparrow Growth C

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+5.17%
ORKA - SYRE
58%
Loosely correlated
+2.11%
XNCR - SYRE
58%
Loosely correlated
+3.66%
BEAM - SYRE
57%
Loosely correlated
+2.49%
RGNX - SYRE
56%
Loosely correlated
-0.66%
APGE - SYRE
55%
Loosely correlated
+4.34%
More

VSTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZLDAF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZLDAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VSTM
1D Price
Change %
VSTM100%
-5.69%
ZLDAF - VSTM
47%
Loosely correlated
N/A
MDGL - VSTM
37%
Loosely correlated
+2.29%
DYN - VSTM
36%
Loosely correlated
+2.41%
SYRE - VSTM
35%
Loosely correlated
+5.17%
VRDN - VSTM
34%
Loosely correlated
+5.60%
More